Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health todayExpanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health today

Mira Precision Health, Based in Mason, Ohio, Announces U.S. Launch of ToxNav® Advantage™ at the 2026 ASCO® GI Cancers Symposium

Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine

MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health today announced the official U.S. launch of ToxNav® Advantage™, a clinically validated pharmacogenomic assay designed to identify cancer patients at increased risk of severe or potentially life-threatening toxicities from fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and capecitabine (XELODA®).

This launch comes amid heightened concern regarding fluoropyrimidine safety in certain patient populations. The U.S. Food and Drug Administration recently updated the XELODA® (capecitabine) prescribing information to include a Black Box Warning highlighting the risk of severe, life-threatening, and potentially fatal toxicities in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. This warning underscores the urgent need for proactive identification of genetically at-risk patients prior to initiating treatment with fluoropyrimidines.

Key features of ToxNav® Advantage™ include:

  • Comprehensive analysis of 23 DPYD gene variants
  • Inclusion of DGLUCY and ENOSF1/TYMS variants predictive of fluoropyrimidine-associated cardiotoxicity (CTRCD) and Hand-Foot Syndrome (HFS)
  • Rapid 48-hour turnaround time for clinically actionable results
  • Clear, clinician-friendly reports that support dose optimization, reduced hospitalizations, and lower treatment-related mortality

The launch will be highlighted by a Mira-sponsored Industry Expert Theater (IET) session at the 2026 ASCO® Gastrointestinal Cancers Symposium in San Francisco, CA.

The 45-minute session, titled “From Oxford to the U.S.: The Clinical Utility Evolution of ToxNav® Advantage™ in Preventing 5-FU/Capecitabine Toxicities,” will be presented by Abdul Rahman Jazieh, MD, MPH, Chief Medical Officer of Mira Precision Health. Dr. Jazieh will discuss a real-world case study of fluoropyrimidine-induced cardiovascular toxicity demonstrating the clinical value of variant testing in identifying at-risk patients and informing care decisions.

Professor David Kerr, CBE, MA, MSc, MD, PhD, DSc, FRCP, founder of the original ToxNav® program, internationally recognized oncology researcher, and Chair of Mira Precision Health’s Scientific Advisory Board, will also be onsite throughout ASCO-GI. As the architect of ToxNav’s scientific foundation and a global leader in fluoropyrimidine toxicity research, Professor Kerr will support the U.S. debut of ToxNav® Advantage™ and be available for expert discussions with clinicians, researchers, and industry stakeholders.

ToxNav® Advantage™ builds on more than a decade of peer-reviewed clinical research and real-world implementation of ToxNav® across U.K. and E.U. healthcare systems. The test analyzes 26 clinically relevant gene variants, including 23 DPYD variants aligned with the Association for Molecular Pathology (AMP) 2025 Tier 1 and Tier 2 classifications, along with additional Oxford-validated markers. ToxNav® Advantage™ uniquely extends fluoropyrimidine toxicity risk assessment beyond DPYD deficiency by incorporating genetic variants associated with cancer therapy–related cardiac dysfunction (CTRCD)—a potentially life-threatening complication—and Hand-Foot Syndrome (HFS), a frequent cause of treatment modification or discontinuation in patients receiving fluoropyrimidines.

“We developed ToxNav® to identify patients with a high likelihood of severe toxicity from 5-FU and capecitabine—two of the most widely prescribed cancer therapies worldwide,” said Professor Kerr. “Through our collaboration with Mira Precision Health, ToxNav® has been optimized for the U.S. market, delivering greater clinical utility and rapid turnaround times that can meaningfully improve patient outcomes.”

“ToxNav® Advantage™ provides oncologists with fast, actionable insights to help prevent life-threatening toxicities before treatment begins,” said Dr. Jazieh. “Our mission is to enable precision-driven care that protects patients across every stage of therapy.”

“As a long-time partner of Mira and strong advocate for life science advancement, we’re excited to see this partnership with Oxford bring life-changing technology to the U.S.,” said Michele Blair, Director of Economic Development for the City of Mason. “We’re leaning in to our ‘Mason Living Lab’ platform, which engages city residents and employees as participants to advance new technology. This program differentiates Mason’s position in the Midwestern ecosystem and accelerates science discovery.”

About Mira Precision Health

Mira Precision Health is a CLIA-certified, high-complexity clinical laboratory headquartered in Mason, Ohio, specializing in precision medicine diagnostics. Through its advanced pharmacogenomic and oncology testing solutions, Mira empowers clinicians nationwide to deliver safer, more personalized cancer care.

About the City of Mason, Ohio

The City of Mason, Ohio, is an established hub for biohealth and biotech life science companies, with focus areas in cardiology, mental health and precision medicine. Mason was one of the first cities in Ohio designated a Premier Life Science Ready Community in 2025 by the Ohio Life Sciences Association for its infrastructure readiness, dedicated support systems, accessible real estate and high-quality resources that make it attractive to life science development. For more information about the City of Mason, visit www.whymason.com or www.imaginemason.org.

For media inquiries, please contact:
Lori Borchers
Vice President, Sales and Marketing
Mira Precision Health
Email: [email protected]
Website: https://www.miraprecision.com/toxnav/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mira-precision-health-based-in-mason-ohio-announces-us-launch-of-toxnav-advantage-at-the-2026-asco-gi-cancers-symposium-302652722.html

SOURCE City of Mason

Market Opportunity
Mira Logo
Mira Price(MIRA)
$0.1227
$0.1227$0.1227
+0.24%
USD
Mira (MIRA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Fed Acts on Economic Signals with Rate Cut

Fed Acts on Economic Signals with Rate Cut

In a significant pivot, the Federal Reserve reduced its benchmark interest rate following a prolonged ten-month hiatus. This decision, reflecting a strategic response to the current economic climate, has captured attention across financial sectors, with both market participants and policymakers keenly evaluating its potential impact.Continue Reading:Fed Acts on Economic Signals with Rate Cut
Share
Coinstats2025/09/18 02:28
Iran’s Central Bank Spends $500M on Crypto Amid Rial Crisis

Iran’s Central Bank Spends $500M on Crypto Amid Rial Crisis

Iran's Central Bank has reportedly acquired more than $500 million in cryptocurrency assets over the past year to mitigate the ongoing currency crisis.
Share
coinlineup2026/01/22 08:59
Unlocking Massive Value: Curve Finance Revenue Sharing Proposal for CRV Holders

Unlocking Massive Value: Curve Finance Revenue Sharing Proposal for CRV Holders

BitcoinWorld Unlocking Massive Value: Curve Finance Revenue Sharing Proposal for CRV Holders The dynamic world of decentralized finance (DeFi) is constantly evolving, bringing forth new opportunities and innovations. A significant development is currently unfolding at Curve Finance, a leading decentralized exchange (DEX). Its founder, Michael Egorov, has put forth an exciting proposal designed to offer a more direct path for token holders to earn revenue. This initiative, centered around a new Curve Finance revenue sharing model, aims to bolster the value for those actively participating in the protocol’s governance. What is the “Yield Basis” Proposal and How Does it Work? At the core of this forward-thinking initiative is a new protocol dubbed Yield Basis. Michael Egorov introduced this concept on the CurveDAO governance forum, outlining a mechanism to distribute sustainable profits directly to CRV holders. Specifically, it targets those who stake their CRV tokens to gain veCRV, which are essential for governance participation within the Curve ecosystem. Let’s break down the initial steps of this innovative proposal: crvUSD Issuance: Before the Yield Basis protocol goes live, $60 million in crvUSD will be issued. Strategic Fund Allocation: The funds generated from the sale of these crvUSD tokens will be strategically deployed into three distinct Bitcoin-based liquidity pools: WBTC, cbBTC, and tBTC. Pool Capping: To ensure balanced risk and diversified exposure, each of these pools will be capped at $10 million. This carefully designed structure aims to establish a robust and consistent income stream, forming the bedrock of a sustainable Curve Finance revenue sharing mechanism. Why is This Curve Finance Revenue Sharing Significant for CRV Holders? This proposal marks a pivotal moment for CRV holders, particularly those dedicated to the long-term health and governance of Curve Finance. Historically, generating revenue for token holders in the DeFi space can often be complex. The Yield Basis proposal simplifies this by offering a more direct and transparent pathway to earnings. By staking CRV for veCRV, holders are not merely engaging in governance; they are now directly positioned to benefit from the protocol’s overall success. The significance of this development is multifaceted: Direct Profit Distribution: veCRV holders are set to receive a substantial share of the profits generated by the Yield Basis protocol. Incentivized Governance: This direct financial incentive encourages more users to stake their CRV, which in turn strengthens the protocol’s decentralized governance structure. Enhanced Value Proposition: The promise of sustainable revenue sharing could significantly boost the inherent value of holding and staking CRV tokens. Ultimately, this move underscores Curve Finance’s dedication to rewarding its committed community and ensuring the long-term vitality of its ecosystem through effective Curve Finance revenue sharing. Understanding the Mechanics: Profit Distribution and Ecosystem Support The distribution model for Yield Basis has been thoughtfully crafted to strike a balance between rewarding veCRV holders and supporting the wider Curve ecosystem. Under the terms of the proposal, a substantial portion of the value generated by Yield Basis will flow back to those who contribute to the protocol’s governance. Returns for veCRV Holders: A significant share, specifically between 35% and 65% of the value generated by Yield Basis, will be distributed to veCRV holders. This flexible range allows for dynamic adjustments based on market conditions and the protocol’s performance. Ecosystem Reserve: Crucially, 25% of the Yield Basis tokens will be reserved exclusively for the Curve ecosystem. This allocation can be utilized for various strategic purposes, such as funding ongoing development, issuing grants, or further incentivizing liquidity providers. This ensures the continuous growth and innovation of the platform. The proposal is currently undergoing a democratic vote on the CurveDAO governance forum, giving the community a direct voice in shaping the future of Curve Finance revenue sharing. The voting period is scheduled to conclude on September 24th. What’s Next for Curve Finance and CRV Holders? The proposed Yield Basis protocol represents a pioneering approach to sustainable revenue generation and community incentivization within the DeFi landscape. If approved by the community, this Curve Finance revenue sharing model has the potential to establish a new benchmark for how decentralized exchanges reward their most dedicated participants. It aims to foster a more robust and engaged community by directly linking governance participation with tangible financial benefits. This strategic move by Michael Egorov and the Curve Finance team highlights a strong commitment to innovation and strengthening the decentralized nature of the protocol. For CRV holders, a thorough understanding of this proposal is crucial for making informed decisions regarding their staking strategies and overall engagement with one of DeFi’s foundational platforms. FAQs about Curve Finance Revenue Sharing Q1: What is the main goal of the Yield Basis proposal? A1: The primary goal is to establish a more direct and sustainable way for CRV token holders who stake their tokens (receiving veCRV) to earn revenue from the Curve Finance protocol. Q2: How will funds be generated for the Yield Basis protocol? A2: Initially, $60 million in crvUSD will be issued and sold. The funds from this sale will then be allocated to three Bitcoin-based pools (WBTC, cbBTC, and tBTC), with each pool capped at $10 million, to generate profits. Q3: Who benefits from the Yield Basis revenue sharing? A3: The proposal states that between 35% and 65% of the value generated by Yield Basis will be returned to veCRV holders, who are CRV stakers participating in governance. Q4: What is the purpose of the 25% reserve for the Curve ecosystem? A4: This 25% reserve of Yield Basis tokens is intended to support the broader Curve ecosystem, potentially funding development, grants, or other initiatives that contribute to the platform’s growth and sustainability. Q5: When is the vote on the Yield Basis proposal? A5: A vote on the proposal is currently underway on the CurveDAO governance forum and is scheduled to run until September 24th. If you found this article insightful and valuable, please consider sharing it with your friends, colleagues, and followers on social media! Your support helps us continue to deliver important DeFi insights and analysis to a wider audience. To learn more about the latest DeFi market trends, explore our article on key developments shaping decentralized finance institutional adoption. This post Unlocking Massive Value: Curve Finance Revenue Sharing Proposal for CRV Holders first appeared on BitcoinWorld.
Share
Coinstats2025/09/18 00:35